Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 19

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 19
---
 been a full -timeProfessor since January 1973, heading for several periods the Departments of Virology and of Molecular Genetics. His research on Interferon, its mechanisms of action and the isolation of the human Interferon -betagene, have led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif ®, Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory focused on human embryonic stem cell (“hESC”) and succeeded to produce nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. Mr. Eran Iohan:Mr.Eran Iohan served on the board of directors of Kadimastem since October of 2022, Mr.Iohan brings with him over 20 years of financial, accounting, and managerial experience, leading IPOs, follow -oninvestments, and complex transaction in Israel and US for technology and bio -technologycompanies. From December of 2019 until today, Mr.Iohan has been a director of My Green Fields. From January of 2019 until current, Mr.Iohan has served as the Founder of Thin Places. From March of 2021 until June 2023, he served as Chief Financial Officer at TurboGen. From January of 2007 and until June of 2019 Mr.Iohan was a Partner, Entertainment & Media Industry Leader at PwC Israel, and served as a staff member in various roles at PwC Israel from January 1998 to December 2006. Mr.Iohan is a Certified Public Accountant